Compare · AVXL vs MRNA
AVXL vs MRNA
Side-by-side comparison of Anavex Life Sciences Corp. (AVXL) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVXL and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $19.80B, about 85.5x AVXL ($231.7M).
- Over the past year, AVXL is down 71.1% and MRNA is up 95.6% - MRNA leads by 166.7 points.
- MRNA has hit the wire 12 times in the past 4 weeks while AVXL has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 6 for AVXL).
- Company
- Anavex Life Sciences Corp.
- Moderna Inc.
- Price
- $2.48-0.80%
- $50.91+1.95%
- Market cap
- $231.7M
- $19.80B
- 1M return
- -19.58%
- +1.72%
- 1Y return
- -71.10%
- +95.58%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 0
- 12
- Recent ratings
- 6
- 25
Anavex Life Sciences Corp.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest AVXL
- Anavex Life Sciences Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
- Anavex Life Sciences Corp. filed SEC Form 8-K: Leadership Update
- SEC Form 3 filed by new insider Kellmeyer Terrie
- SEC Form NT 10-Q filed by Anavex Life Sciences Corp.
- Anavex Life Sciences Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
- Rodman & Renshaw initiated coverage on Anavex with a new price target
- SEC Form 3 filed by new insider Paeger Axel
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease
Latest MRNA
- Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
- Chief Legal Officer Klinger Shannon Thyme exercised 15,269 shares at a strike of $7.04, sold $173,550 worth of shares (3,471 units at $50.00) as part of a pre-agreed trading plan and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 9% to 73,561 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M converted options into 11,798 shares and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 10% to 65,687 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Mock James M converted options into 2,475 shares and covered exercise/tax liability with 1,197 shares, increasing direct ownership by 2% to 59,594 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 2,165 shares and covered exercise/tax liability with 1,047 shares, increasing direct ownership by 2% to 67,468 units (SEC Form 4) (tax withholding)
- President Hoge Stephen converted options into 9,282 shares and covered exercise/tax liability with 4,488 shares, increasing direct ownership by 0.32% to 1,483,848 units (SEC Form 4) to satisfy tax liability
- Moderna to Present at Upcoming Conference in June 2026
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
- Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
- Chief Financial Officer Mock James M converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.98% to 58,316 units (SEC Form 4) to satisfy tax liability